The EMA has published guidance on registry-based studies as a tool to generate RWE
By EsqSocial Corporation 22/10/20
On 24 September 2020, the European Medicines Agency (“EMA”) published a draft Guideline on registry-based studies. The EMA’s intention is to enhance the use of registry-based studies as a source of real-world evidence (RWE)....
By: Hogan Lovells